The Distinctive Activation of Toll-Like Receptor 4 in Human Samples with Sepsis.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 09 2022
Historique:
received: 29 08 2022
revised: 19 09 2022
accepted: 23 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 18 10 2022
Statut: epublish

Résumé

Clinical success of Toll-Like receptor-4 (TLR-4) antagonists in sepsis therapy has thus far been lacking. As inhibition of a receptor can only be useful if the receptor is active, stratification of patients with active TLR-4 would be desirable. Our aim was to establish an assay to quantify phosphorylated TLR-4 using the proximity ligation assay (PLA). HEK293 TLR4/MD2/CD14 as well as THP-1 cells were stimulated with LPS and the activation of TLR-4 was measured using the PLA. Furthermore, peripheral blood mononuclear cells (PBMCs) from 25 sepsis patients were used to show the feasibility of this assay in clinical material. Activation of TLR-4 in these samples was compared to the PBMCs of 11 healthy individuals. We could show a transient activation of TLR-4 in both cell lines. Five min after the LPS stimulation, the signal increased 6.7-fold in the HEK293 cells and 4.3-fold in the THP-1 cells. The assay also worked well in the PBMCs of septic patients. Phosphorylation of TLR-4 at study inclusion was 2.9 times higher in septic patients compared to healthy volunteers. To conclude, we established a diagnostic assay that is able to quantify the phosphorylation of TLR-4 in cell culture and in clinical samples of sepsis patients. This makes large-scale stratification of sepsis patients for their TLR-4 activation status possible.

Identifiants

pubmed: 36230982
pii: cells11193020
doi: 10.3390/cells11193020
pmc: PMC9563554
pii:
doi:

Substances chimiques

Lipopolysaccharides 0
TLR4 protein, human 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Enferm Infecc Microbiol Clin (Engl Ed). 2022 Apr;40(4):183-186
pubmed: 35473989
Am J Pathol. 2009 Oct;175(4):1631-7
pubmed: 19717644
Stem Cell Reports. 2022 Mar 8;17(3):538-555
pubmed: 35180397
Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):328-38
pubmed: 10660480
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Anasthesiol Intensivmed Notfallmed Schmerzther. 2022 May;57(5):360-370
pubmed: 35588749
J Leukoc Biol. 2017 Jan;101(1):107-119
pubmed: 27780875
J Biol Chem. 2007 Jun 1;282(22):16042-53
pubmed: 17392283
BMC Anesthesiol. 2022 Jan 5;22(1):12
pubmed: 34986787
EMBO J. 2006 Feb 22;25(4):683-92
pubmed: 16467847
Blood. 2009 Feb 12;113(7):1399-407
pubmed: 18757776
Sci Rep. 2015 Jul 23;5:12317
pubmed: 26202090
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
Shock. 2011 Dec;36(6):613-20
pubmed: 22089127
JAMA. 2013 Mar 20;309(11):1154-62
pubmed: 23512062
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
Nat Rev Immunol. 2013 Sep;13(9):679-92
pubmed: 23954936
Front Immunol. 2020 Nov 27;11:585146
pubmed: 33329561
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Int J Mol Sci. 2020 Feb 07;21(3):
pubmed: 32046099

Auteurs

Patrick Thon (P)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Katharina Rump (K)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Annika Knorr (A)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Birte Dyck (B)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Dominik Ziehe (D)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Matthias Unterberg (M)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Hartmuth Nowak (H)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Lars Bergmann (L)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Alexander Wolf (A)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Maha Bazzi (M)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Jennifer Orlowski (J)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Marcus Peters (M)

Molekulare Immunologie, Ruhr-University Bochum, 44780 Bochum, Germany.

Alexander Zarbock (A)

Klinik für Anästhesiologie, Operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Münster, 48149 Münster, Germany.

Thorsten Brenner (T)

Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.

Michael Adamzik (M)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Tim Rahmel (T)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Björn Koos (B)

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH